Use of Hepatoprotectors During Tuberculosis Chemotherapy: Review of the Russian and International Studies

Старшинова, Анна; Belyaeva, Ekaterina; Пантелеев, А. М.; Павлова, М. В.

doi:10.21292/2075-1230-2018-96-10-63-69

Cited by 3 publications

(6 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The incidence of side effects from the liver is 44-60% of cases, which is confirmed by the results of studies by many researchers (Ivаnovа and Borisov 2018;Stаrshinovа et al 2018). It was found that hepatotoxicity is more often associated with taking first-line anti-TB drugs -Rifampicin (67%), Pyrazinamide (30%), and Isoniazid (7%) (Schaaf et al 2016;Stаrshinovа et al 2018). To prevent the development of toxic reactions, at the same time with the start of anti-tuberculosis chemotherapy, it is recommended to prescribe corrective drugs to patients.…”

Section: Anti-tb Drugs For Childrensupporting

confidence: 57%

“…According to the literature Borisov 2017, 2018;Schegertsov et al 2018;Athulnadh et al 2020;Laghari et al 2020;van der Walt et al 2020), the most frequent side effects associated with the use of chemotherapy in patients with tuberculosis infection are toxic reactions (hepatotoxicity, gastrotoxicity, nephrotoxicity) and allergic reactions. The incidence of side effects from the liver is 44-60% of cases, which is confirmed by the results of studies by many researchers (Ivаnovа and Borisov 2018;Stаrshinovа et al 2018). It was found that hepatotoxicity is more often associated with taking first-line anti-TB drugs -Rifampicin (67%), Pyrazinamide (30%), and Isoniazid (7%) (Schaaf et al 2016;Stаrshinovа et al 2018).…”

Section: Anti-tb Drugs For Childrenmentioning

confidence: 69%

See 1 more Smart Citation

Modern approaches to pharmacotherapy of tuberculosis infection in children

Новиков¹,

Usacheva²,

Myakisheva³

2021

RRP

View full text Add to dashboard Cite

Anti-TB drugs for children: Aetiotropic therapy is used for the treatment of tuberculosis (TB) in children, as well as in adult patients. Anti-tuberculosis drugs (anti-TB drugs) are divided into 3 lines, taking into account drug sensitivity in Mycobacterium tuberculosis (MBT). First-line anti-TB drugs (basic) are used to treat TB caused by drug-susceptible MBT. Second- and third-line (reserve) drugs are recommended for the treatment of MBT-induced multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB, respectively. Stages and regimens to treat tuberculosis: Chemotherapy of tuberculosis in children is carried out in 2 stages (intensive treatment and continuation of treatment) and includes 5 regimens. Each regimen assumes a certain combination of anti-TB drugs, indicating the duration and frequency of their administration. The final chemotherapy regimen is chosen only according to the results of determining the drug sensitivity. To improve the TB epidemic among children, it is important to improve the regimens for the use of anti-TB drugs. The effectiveness of anti-tuberculosis pharmacotherapy is largely determined by the MBT sensitivity and the rational choice of the chemotherapy regimen. The wrong choice of a chemotherapy regimen or its violation threatens to reduce the effectiveness of pharmacotherapy and expand the spectrum of resistance of the pathogen. The development of fixed-dose combination anti-TB drugs and special dosage forms for children will improve the quality of chemotherapy and adherence to treatment. Pharmacoeconomic studies are needed to increase the effectiveness of drug pharmacotherapy for tuberculosis infection in children and to optimize the costs of its implementation.

show abstract

Section: Anti-tb Drugs For Childrensupporting

confidence: 57%

Section: Anti-tb Drugs For Childrenmentioning

confidence: 69%

Modern approaches to pharmacotherapy of tuberculosis infection in children

Новиков¹,

Usacheva²,

Myakisheva³

2021

RRP

View full text Add to dashboard Cite

show abstract

“…Согласно проведенным исследованиям, причиной возникновения нежелательных явлений является не только непосредственное воздействие лекарственного препарата, но и ряд факторов, таких как возраст, пол, сопутствующие заболевания, индивидуальная чувствительность организма к лекарственному веществу и непосредственное воздействие самого инфекционного агента на гепатоциты [21].…”

Section: резюмеunclassified

“…1. МСКТ пациента М., 61 год, с двусторонней пневмонией, больного COVID-19 том 7 №6 / 2020 Анестезиология и реаниматология / Pain, Critical Care and Anesthesia мальных показателях общего билирубина -20,3 мкмоль/л, щелочная фосфатаза в норме (93 Ед/л), что характеризует гепатоцеллюлярный тип поражения печени [21]. Показатели свертываемости крови без существенных изменений (активированное частичное тромбопластиновое время -27,1 с; международное нормализованное отношение -1,08; протромбин по Квику -3,38 мг на 100 мл плазмы крови; протромбиновое время -14,8), за исключением некоторого снижения протромбинового индекса -86 %.…”

Section: анестезиология и реаниматология / Pain Critical Care and Anunclassified

Possibilities for correcting hepatotoxic reactions during therapy in patients with COVID-19 (case report)

Смок

Малкова

Кудлай

et al. 2020

Transl. med. (Print)

View full text Add to dashboard Cite

In 2020, a pandemic of the new coronavirus infection (COVID-19) began. Treatment of this infection is limited by the lack of effective etiological treatment, which requires the selection of empirical and symptomatic therapy. The obtained some effectiveness of the use of antimalarial drugs, antiretroviral drugs in combination with antibacterial therapy made it possible to recommend it for use in the treatment regimen for patients with COVID-19. However, these drugs provoke the development of undesirable side reactions that require correction to continue treatment. Considering the need to use complex therapy in the treatment of patients with COVID-19 and the direct effect of the virus on liver cells, the likelihood of developing hepatotoxicity is quite high. The described cases of liver damage are characterized by impaired functional activity, an increase in the level of liver function tests, the development of small-drop fatty infiltration and a mild inflammatory reaction in the liver lobules. The development of these complications requires the hepatoprotective drugs, which increase the liver’s resistance to the damaging effects of various pathogens and help restore the functional activity of hepatocytes. According to the conducted studies, hepatotropic drug inosine+ + meglumine + methionine + nicotinamide + succinic acid and reamberin contribute to the normalization of lipid metabolism, a decrease in the level of enzyme markers of liver damage. The article presents the complex treatment with lopinavir + ritonavir. Thanks to hepatoprotective therapy, a week later, a decrease in ALT, alpha-amylase, blood counts to normal values was achieved.

show abstract

“…Гепатотоксические реакции (ГТР) у больных туберкулезом, получающих противотуберкулезные препараты (ПТП), отмечаются, по данным разных авторов, в 44-60% случаев и проявляются нарушением дезинтоксикационной, белковосинтетической и других функций печени [6]. Согласно исследованиям, у впервые выявленных больных туберкулезом и у больных, получавших лечение по 1-му режиму химиотерапии, основными виновниками развития ГТР являлись рифампицин (67% случаев), пиразинамид (30%) и изониазид (7%) [3].…”

unclassified

Parameters of hepatotoxic reactions caused by the combination of first line anti-tuberculosis drugs in rats with different acetylation phenotypes

Можокина¹,

Kazakov²,

Зюзя³

et al. 2020

Tuberk. bolezni lëgk.

View full text Add to dashboard Cite

The objective: in the experiment, to study specific parameters of manifestations of hepatotoxic reactions to the combination of anti-tuberculosis drugs containing isoniazid and rifampicin in rats with different acetylation phenotypes. Subjects and methods. Liver damage was modeled in rats, old females, belonging to the phenotype of rapid acetylation, and in mature males, belonging to the phenotype of slow acetylation, with a combination of basic anti-tuberculosis drugs, which were administered for 14 days. Hepatotoxic reactions were assessed by clinical observations of rats, biochemical parameters and morphological changes in the liver, which were compared with intact animals. Results of the study: in female rats (fast acetylators of isoniazid), signs of the cytolytic mechanism of liver damage prevailed (more significant elevation of ALT activity, pronounced duration of thiopental sleep, pronounced hydropic degeneration of hepatocytes with the presence of hepatocyte necrosis, venous congestion and edema of the portal tracts). In males (with the phenotype of slow acetylation of isoniazid), a significant elevation of total and direct bilirubin levels, AST activity and, to a lesser extent, ALT were observed, i.e., signs of a mixed mechanism of liver damage (cholestatic and cytolytic).

show abstract

Use of Hepatoprotectors During Tuberculosis Chemotherapy: Review of the Russian and International Studies

Cited by 3 publications

References 12 publications

Modern approaches to pharmacotherapy of tuberculosis infection in children

Modern approaches to pharmacotherapy of tuberculosis infection in children

Possibilities for correcting hepatotoxic reactions during therapy in patients with COVID-19 (case report)

Parameters of hepatotoxic reactions caused by the combination of first line anti-tuberculosis drugs in rats with different acetylation phenotypes

Contact Info

Product

Resources

About